Positive overall survival data from the phase II KATE-2 study were presented at the 2019 ESMO Annual Meeting. Leisha Emens, MD, shares the results.
Leisha Emens, MD
Advertisement
Articles by Leisha Emens, MD
Advertisement
Latest Updated Articles
Atezolizumab Added to T-DM1 Improves OS and PFS in HER2+ Breast CancerPublished: November 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
